Farxiga (Dapagliflozin) Pediatric Safety: What Parents and Clinicians Should Know About Use Under Age 12

FDA Approval Status and Labeled Age Restrictions

Dapagliflozin carries no pediatric indication of any kind. The drug is approved for three adult conditions: type 2 diabetes (2014), heart failure with reduced ejection fraction (2020), and chronic kidney disease (2021) [1][2]. Each of these approvals was based on trials that excluded participants younger than 18.

The FDA prescribing information for Farxiga states clearly that "safety and effectiveness in pediatric patients have not been established" [2]. This language means no dose has been validated, no pharmacokinetic profile has been characterized, and no risk-benefit assessment has been completed for any child, let alone one under 12. AstraZeneca is required under the Pediatric Research Equity Act (PREA) to submit pediatric study plans, but completed data for younger age groups have not been published as of May 2026 [3].

By comparison, empagliflozin (Jardiance) received FDA approval in June 2023 for type 2 diabetes in children aged 10 and older, based on the DINAMO trial (N=158) [4]. That approval remains the only SGLT2 inhibitor clearance for any pediatric population. Even empagliflozin's approval does not extend below age 10.

Why No Pediatric Trials Exist for Children Under 12

Running drug trials in very young children requires clearing high ethical and regulatory bars. The FDA and European Medicines Agency (EMA) both mandate that adult and adolescent data exist before younger cohorts are enrolled. Type 2 diabetes itself is rare in children under 10, with incidence estimated at 0.6 per 100 to 000 in the 5-to-9 age band according to SEARCH for Diabetes in Youth data [5].

The low disease prevalence creates a practical enrollment barrier. Trial sites cannot recruit enough participants to power a safety study without a multinational, multi-year design. Heart failure and CKD are even less common in this age group, and when they do occur, the underlying etiologies (congenital heart disease, CAKUT) differ sharply from the adult phenotypes that dapagliflozin targets [6]. A drug proven to reduce hospitalizations in adults with ischemic cardiomyopathy cannot be assumed to behave identically in a 7-year-old with a single ventricle repair.

SGLT2 Inhibitor Mechanism and Pediatric-Specific Risks

SGLT2 inhibitors work by blocking sodium-glucose cotransporter 2 in the S1 and S2 segments of the proximal renal tubule, which prevents roughly 30% to 50% of filtered glucose from being reabsorbed [7]. The resulting glycosuria lowers blood glucose independently of insulin. In adults, this mechanism also reduces intraglomerular pressure and produces a mild osmotic diuresis.

Children under 12 present distinct physiological considerations. Renal tubular function does not reach adult-equivalent maturity until mid-childhood, and glomerular filtration rate normalized to body surface area continues to rise through the first decade of life [8]. Blocking SGLT2 in a still-maturing nephron population raises theoretical concerns about tubular workload redistribution to SGLT1 and downstream transporters.

Dehydration risk is also higher. Younger children have a higher ratio of body surface area to body mass, lose proportionally more fluid through insensible losses, and may not reliably communicate thirst. The osmotic diuretic effect of SGLT2 inhibition compounds this vulnerability. In a 2020 pharmacovigilance review of SGLT2 inhibitor adverse events reported to the FDA Adverse Event Reporting System (FAERS), volume depletion events occurred in approximately 1.5% of all reported cases across the class [9].

Diabetic Ketoacidosis: The Highest-Priority Safety Signal

Euglycemic DKA is the most clinically consequential adverse effect of SGLT2 inhibitors. Unlike classic DKA, blood glucose may remain below 250 mg/dL, which delays recognition. Across the SGLT2 class in adult trials, DKA incidence ranges from 0.1% in DECLARE-TIMI 58 (N=17,160) to 0.3% in smaller registries [10][11].

Children face compounding risk factors. Pediatric patients with type 2 diabetes may also carry autoimmune markers (so-called "double diabetes"), and those with residual beta-cell function fluctuations are more susceptible to ketosis during illness or fasting [12]. A child who skips meals, exercises heavily, or develops a gastrointestinal illness while taking an SGLT2 inhibitor faces a convergence of ketogenic triggers. The FDA issued a Drug Safety Communication in 2015 warning of DKA risk across the entire SGLT2 class, recommending that clinicians check ketones in any patient presenting with nausea, vomiting, abdominal pain, or malaise, even with near-normal glucose [13].

No published case series has documented euglycemic DKA from dapagliflozin in a child under 12, but this absence of data reflects the absence of use, not confirmed safety.

Growth, Development, and Caloric Diversion

SGLT2 inhibition diverts 60 to 80 grams of glucose per day into the urine in adults taking 10 mg of dapagliflozin, representing roughly 240 to 320 kilocalories of lost energy substrate [14]. This caloric loss drives the modest weight reduction seen in adult trials (typically 2 to 3 kg over 24 weeks).

In a growing child, that caloric diversion raises a different set of concerns. Children under 12 require caloric surplus for linear growth, bone mineralization, and neurodevelopment. No study has assessed whether chronic urinary glucose losses from SGLT2 inhibition affect height velocity, bone density accrual, or pubertal timing. The Endocrine Society's 2017 pediatric obesity guidelines recommend that any pharmacotherapy used in children be evaluated for effects on growth trajectories, not just glycemic endpoints [15]. Dapagliflozin has not undergone this evaluation.

Weight loss that is therapeutically desirable in a 55-year-old with metabolic syndrome could be harmful in a 9-year-old whose growth plates are still open.

What the Adult Trial Data Can and Cannot Tell Us

The three landmark dapagliflozin trials provide strong efficacy evidence in adults but limited extrapolation to pediatric physiology.

DAPA-HF (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death (HR 0.74 to 95% CI 0.65 to 0.85) in adults with HFrEF, with a median age of 66 years [1]. DAPA-CKD (N=4,304) showed a 39% reduction in the composite renal endpoint (HR 0.61 to 95% CI 0.51 to 0.72) in adults with CKD regardless of diabetes status, median age 62 [16]. DECLARE-TIMI 58 (N=17,160) evaluated cardiovascular outcomes in adults with type 2 diabetes and established or risk-factor-only cardiovascular disease [10].

None of these trials included patients under 18. The heart failure and CKD phenotypes studied (ischemic cardiomyopathy, diabetic nephropathy, IgA nephropathy) differ from the congenital and developmental etiologies that predominate in pediatric cardiology and nephrology. Extrapolating a hazard ratio from a 66-year-old with ischemic HFrEF to a child with dilated cardiomyopathy requires assumptions that current evidence cannot support.

Genital Infections and Urinary Tract Risks in Children

SGLT2 inhibitors increase urinary glucose concentration, which promotes fungal overgrowth. In adult trials, genital mycotic infections occurred in 5% to 9% of women and 3% to 5% of men taking dapagliflozin versus approximately 1% on placebo [17]. Urinary tract infection rates were modestly elevated as well.

Pre-pubertal children have different urogenital anatomy and hygiene patterns. Girls under 12 have a shorter urethra, absence of estrogenized vaginal mucosa, and less self-directed hygiene capacity. Boys may have phimosis that traps glucose-rich urine. These anatomic factors could amplify infection risk beyond what adult data predict. The American Academy of Pediatrics has documented that recurrent UTIs in young children can cause renal scarring, a consequence that carries lifelong implications [18]. Adding a drug that increases glycosuria to this population introduces a risk with no studied counterbalance of benefit.

Off-Label Prescribing: Legal Framework and Clinical Reality

Physicians can legally prescribe dapagliflozin off-label to a child. Off-label prescribing accounts for an estimated 50% to 75% of all pediatric prescriptions in the United States, according to a 2014 AAP analysis [19]. The legal permission does not equal clinical endorsement.

For a drug to be prescribed off-label with reasonable justification, clinicians typically require at least one of the following: pediatric pharmacokinetic data, case series demonstrating safety in the target age group, or a guideline recommendation from a recognized body. Dapagliflozin has none of these for children under 12. The American Diabetes Association's Standards of Care (2024) list metformin and insulin as the only pharmacotherapies recommended for type 2 diabetes in children, with liraglutide approved down to age 10 [20]. SGLT2 inhibitors are not mentioned as a pediatric option.

Any clinician considering off-label dapagliflozin in a child under 12 should document the clinical rationale, obtain informed consent that explicitly states the drug lacks pediatric approval, and implement close monitoring for DKA, volume depletion, genital infections, and growth parameters.

Monitoring Recommendations If Off-Label Use Occurs

No validated pediatric monitoring protocol exists for dapagliflozin. Based on adult safety data and pediatric physiology, a reasonable minimum surveillance framework would include:

• Baseline labs: fasting glucose, HbA1c, serum creatinine with estimated GFR, serum bicarbonate, beta-hydroxybutyrate, urinalysis, and liver enzymes.
• Follow-up schedule: every 4 weeks for the first 12 weeks, then every 8 to 12 weeks. Adult protocols typically use 12-week intervals, but pediatric off-label use warrants closer surveillance.
• Growth tracking: height, weight, and BMI plotted on CDC or WHO growth charts at every visit.
• DKA education: families should receive written instructions on checking urine or blood ketones during any illness, missed meals, or perioperative periods. The FDA 2015 safety communication guidance applies with added urgency in children [13].
• Hydration counseling: minimum fluid intake targets adjusted for body weight, with specific guidance for hot weather and physical activity.
• Genital hygiene: age-appropriate education for the child and caregivers, with a low threshold for urine culture if symptoms develop.

What May Change: Pending and Future Pediatric Studies

AstraZeneca's PREA commitments include pediatric study plans filed with the FDA, though specific protocol designs and enrollment timelines for children under 12 have not been publicly disclosed as of May 2026 [3]. The ClinicalTrials.gov registry lists no active or recruiting interventional trial of dapagliflozin in children under 10 [21].

The EMA's Paediatric Committee (PDCO) has granted deferrals for dapagliflozin pediatric development in certain indications, acknowledging that the drug may eventually prove useful in younger populations but that adult data must mature first [22]. If the DINAMO-like model is replicated (empagliflozin studied in adolescents 10 to 17, then potentially extended downward), a dapagliflozin pediatric trial in children 10 and older could precede any study in those under 10 by several years.

Until trial results emerge, the clinical position remains straightforward: dapagliflozin should not be used in children under 12 outside of a research protocol.